RxDoctor Payments Data

Amit Dhingra, MD

Pulmonary Disease · Peoria, AZNPI 1437122397

Payments from drug & device makers

$10,976in general payments, 2019–2025

Across 481 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • United Therapeutics Corporation$1K
  • AstraZeneca$981
  • GSK$977
  • Actelion Pharmaceuticals US, Inc.$872
  • Sanofi$713
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$10,85499%
  • Education$1221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,976 in reported general payments places this provider in the 70th percentile of 250 pulmonary disease providers in Arizona.

See all pulmonary disease providers in Arizona

Medicare billing

Part B allowed, 2024
$234,526
Medicare patients
524
Services billed
2,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate39$493,371
Spiriva RespimatTiotropium Bromide200$137,040
Advair HfaFluticasone Propion/Salmeterol347$131,963
Trelegy ElliptaFluticasone/Umeclidin/Vilanter164$125,265
Breo ElliptaFluticasone/Vilanterol247$118,022
Dupixent SyringeDupilumab26$106,029
Stiolto RespimatTiotropium Br/Olodaterol Hcl143$82,837
Breztri AerosphereBudesonide/Glycopyr/Formoterol104$73,153
SymbicortBudesonide/Formoterol Fumarate208$60,665
Incruse ElliptaUmeclidinium Bromide139$55,027
Fluticasone-SalmeterolFluticasone Propion/Salmeterol196$40,554
Spiriva HandihalerTiotropium Bromide36$32,469
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr44$26,835
XareltoRivaroxaban21$23,333
Arnuity ElliptaFluticasone Furoate95$22,857

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$1,505$713,249382 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta$977$348,006689 claims
AstraZenecaBreztri Aerosphere, Symbicort$981$133,817312 claims
MerckDulera$134$16,07431 claims
PfizerEliquis$13$14,20720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 250 pulmonary disease providers in Arizona.

Other pulmonary disease in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →